insights_auto
Kwa nini DMYD-B imeongezeka kwa 3.75%?
Fahamu zaidichevron_right
DMYD-B:STO
Diamyd Medical AB
SEK 1.05
arrow_upward
+3.75%(+0.038) Siku 1
13 Okt, 11:24:11 GMT +2 · SEK
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya DMYD-B...
Fungua
SEK 1.03
Juu
SEK 1.08
Chini
SEK 1.01
Mtaji wa soko
159.36M
Wastani wa kiasi cha mauzo
elfu 796.34
Kiasi cha mauzo ya hisa
elfu 459.51
Juu kwa wiki 52
SEK 17.88
Chini kwa wiki 52
SEK 0.90
EPS
-SEK 1.76
Hisa za wawekezaji
134.00M
Idadi ya wafanyakazi
42
Fungua
SEK 1.03
Juu
SEK 1.08
Chini
SEK 1.01
Mtaji wa soko
159.36M
Wastani wa kiasi cha mauzo
elfu 796.34
Kiasi cha mauzo ya hisa
elfu 459.51
Juu kwa wiki 52
SEK 17.88
Chini kwa wiki 52
SEK 0.90
EPS
-SEK 1.76
Hisa za wawekezaji
134.00M
Idadi ya wafanyakazi
42
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
The Motley Fool
·
dakika 6 zilizopita
Prediction: A Stock Market Crash Is Coming. Here's What Investors Should Do Based on Almost 7 Decades' Worth of History.
Inc.com
·
dakika 26 zilizopita
The S&P 500’s Bull Market Just Turned 4. History Says the Next Year Is What Matters Most
Benzinga
·
dakika 19 zilizopita
Nasdaq Down Over 100 Points as Memory Stocks Decline: Fear & Greed Index Remains in ‘Neutral’ Zone
Wasifu
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
Kuhusu Diamyd Medical AB
Afisa Mkuu Mtendaji (CEO)Ulf Hannelius
Wafanyakazi42
Lilianzishwa1984
Makao makuu-
Sekta-
Tovutidiamyd.com